Compare ETFs: IBB vs. LON:BTEC
IBB
LON:BTEC
Comparison
Average Return
In the past year, IBB returned a total of 48.40%, which is slightly higher than LON:BTEC's 47.46% return. Over the past 5 years, IBB has had annualized average returns of 4.50%, compared to 6.25% for LON:BTEC. These numbers are adjusted for stock splits and assume dividends are reinvested.
Top 25 Holdings
| IBB - iShares Biotechnology ETF | |||
|---|---|---|---|
| No. | Symbol | Name | Weight |
| 1 | GILD | Gilead Sciences, Inc. | 8.16% |
| 2 | VRTX | Vertex Pharmaceuticals Incorporated | 7.65% |
| 3 | AMGN | Amgen Inc. | 7.53% |
| 4 | REGN | Regeneron Pharmaceuticals, Inc. | 5.57% |
| 5 | MRNA | Moderna, Inc. | 5.02% |
| 6 | NTRA | Natera, Inc. | 3.88% |
| 7 | ARGX | argenx SE | 3.77% |
| 8 | ILMN | Illumina, Inc. | 2.91% |
| 9 | RVMD | Revolution Medicines, Inc. | 2.72% |
| 10 | ALNY | Alnylam Pharmaceuticals, Inc. | 2.35% |
| 11 | BIIB | Biogen Inc. | 2.34% |
| 12 | ONC | BeOne Medicines AG | 2.14% |
| 13 | INSM | Insmed Incorporated | 1.85% |
| 14 | INCY | Incyte Corporation | 1.77% |
| 15 | UTHR | United Therapeutics Corporation | 1.38% |
| 16 | GMAB | Genmab A/S | 1.36% |
| 17 | ROIV | Roivant Sciences Ltd. | 1.34% |
| 18 | ASND | Ascendis Pharma A/S | 1.00% |
| 19 | NBIX | Neurocrine Biosciences, Inc. | 0.99% |
| 20 | MEDP | Medpace Holdings, Inc. | 0.98% |
| 21 | EXEL | Exelixis, Inc. | 0.98% |
| 22 | CRL | Charles River Laboratories International, Inc. | 0.98% |
| 23 | HALO | Halozyme Therapeutics, Inc. | 0.91% |
| 24 | TWST | Twist Bioscience Corporation | 0.83% |
| 25 | BMRN | BioMarin Pharmaceutical Inc. | 0.83% |
| View IBB holdings | |||
| LON:BTEC - iShares NASDAQ US Biotechnology UCITS ETF | |||
|---|---|---|---|
| No. | Symbol | Name | Weight |
| 1 | GILD | Gilead Sciences, Inc. | 8.39% |
| 2 | VRTX | Vertex Pharmaceuticals Incorporated | 7.68% |
| 3 | AMGN | Amgen Inc. | 7.65% |
| 4 | REGN | Regeneron Pharmaceuticals, Inc. | 5.38% |
| 5 | MRNA | Moderna, Inc. | 4.82% |
| 6 | RVMD | Revolution Medicines, Inc. | 2.71% |
| 7 | ILMN | Illumina, Inc. | 2.56% |
| 8 | BIIB | Biogen Inc. | 2.23% |
| 9 | ALNY | Alnylam Pharmaceuticals, Inc. | 2.19% |
| 10 | ROIV | Roivant Sciences Ltd. | 1.77% |
| 11 | INSM | Insmed Incorporated | 1.71% |
| 12 | ARGX | argenx SE | 1.71% |
| 13 | RPRX | Royalty Pharma plc | 1.70% |
| 14 | INCY | Incyte Corporation | 1.68% |
| 15 | GH | Guardant Health, Inc. | 1.57% |
| 16 | UTHR | United Therapeutics Corporation | 1.39% |
| 17 | VTRS | Viatris Inc. | 1.30% |
| 18 | MEDP | Medpace Holdings, Inc. | 1.14% |
| 19 | JAZZ | Jazz Pharmaceuticals plc | 1.01% |
| 20 | NBIX | Neurocrine Biosciences, Inc. | 0.94% |
| 21 | EXEL | Exelixis, Inc. | 0.93% |
| 22 | ASND | Ascendis Pharma A/S | 0.91% |
| 23 | TEM | Tempus AI, Inc. | 0.89% |
| 24 | BBIO | BridgeBio Pharma, Inc. | 0.87% |
| 25 | SMMT | Summit Therapeutics Inc. | 0.87% |
| View LON:BTEC holdings | |||